Evidence map›Paper›PMID 24887457›Full record

ArticleNature communications2014

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.

Michael R Green, Carolina Vicente-Dueñas, Isabel Romero-Camarero, Chih Long Liu, Bo Dai, Inés González-Herrero, Idoia García-Ramírez, Esther Alonso-Escudero, Javeed Iqbal, Wing C Chan and 17 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 86 citations in OpenAlex.

  1. B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and Beyond.International journal of molecular sciences · 2024
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. B cell lymphoma 6A regulates immune development and function in zebrafish.Frontiers in cellular and infection microbiology · 2022
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies.Journal of clinical and experimental hematopathology : JCEH · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Are Leukaemic Stem Cells Restricted to a Single Cell Lineage?International journal of molecular sciences · 2019
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 10 institutions in 2 countries.

Michael R Green1] Divisions of Oncology and Hematology, Department of Medicine, School of Medicine, Stanford University, Stanford, California 94305, USA [2].
Carolina Vicente-Dueñas1] Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, 37007 Salamanca, Spain [2] Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain [3].
Isabel Romero-Camarero1] Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, 37007 Salamanca, Spain [2] Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Chih Long LiuDivisions of Oncology and Hematology, Department of Medicine, School of Medicine, Stanford University, Stanford, California 94305, USA.
Bo DaiDivisions of Oncology and Hematology, Department of Medicine, School of Medicine, Stanford University, Stanford, California 94305, USA.
Inés González-Herrero1] Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, 37007 Salamanca, Spain [2] Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Idoia García-Ramírez1] Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, 37007 Salamanca, Spain [2] Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Esther Alonso-Escudero1] Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, 37007 Salamanca, Spain [2] Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Javeed IqbalDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA.
Wing C ChanDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA.
Elena Campos-SanchezCentro de Biología Molecular Severo Ochoa, CSIC/Universidad Autónoma de Madrid, c/Nicolás Cabrera, n° 1, Campus de Cantoblanco, 28049 Madrid, Spain.
Alberto OrfaoServicio de Citometría and Departamento de Medicina, Universidad de Salamanca, 37007 Salamanca, Spain.
Belén PintadoGenetically Engineered Mouse Facility, CNB-CSIC, 28006 Madrid, Spain.
Teresa Flores1] Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain [2] Departamento de Anatomía Patológica, Universidad de Salamanca, 37007 Salamanca, Spain.
Oscar BlancoDepartamento de Anatomía Patológica, Universidad de Salamanca, 37007 Salamanca, Spain.
Rafael Jiménez1] Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain [2] Departamento de Fisiología y Farmacología, Universidad de Salamanca, Campus M. Unamuno s/n, 37007 Salamanca, Spain.
Jose Angel Martínez-ClimentDivision of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
Francisco Javier García CriadoDepartamento de Cirugía, Universidad de Salamanca, 37007 Salamanca, Spain.
María Begoña García CenadorDepartamento de Cirugía, Universidad de Salamanca, 37007 Salamanca, Spain.
Shuchun ZhaoDepartment of Pathology, Stanford University School of Medicine, Stanford, California, 94305 USA.
Yasodha NatkunamDepartment of Pathology, Stanford University School of Medicine, Stanford, California, 94305 USA.
Izidore S LossosDivision of Hematology-Oncology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida 33136, USA.
Ravindra MajetiDivisions of Oncology and Hematology, Department of Medicine, School of Medicine, Stanford University, Stanford, California 94305, USA.
Ari MelnickDepartments of Medicine and Pharmacology, Weill Cornell Medical College, New York, New York 10021, USA.
César CobaledaCentro de Biología Molecular Severo Ochoa, CSIC/Universidad Autónoma de Madrid, c/Nicolás Cabrera, n° 1, Campus de Cantoblanco, 28049 Madrid, Spain.
Ash A Alizadeh1] Divisions of Oncology and Hematology, Department of Medicine, School of Medicine, Stanford University, Stanford, California 94305, USA [2].
Isidro Sánchez-García1] Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, 37007 Salamanca, Spain [2] Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain [3].
Universidad de Salamanca · ESStanford University · USInstituto de Investigación Biomédica de Salamanca · ESUniversity of Nebraska Medical Center · USCentro de Biología Molecular Severo Ochoa · ESCentro Nacional de Biotecnología · ESCornell University · USUniversidad Autónoma de Madrid · ESUniversidad de Navarra · ESUniversity of Miami · US

Funding

Interrogation of individual cells to identify progenitors and their nichesU01HL099999 · NHLBI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2009 to 2015
$7.8M
Interrogation of individual cells to identify progenitor cells and their nichesU01HL099995 · NHLBI · STANFORD UNIVERSITY · PI KRASNOW, MARK A · 2009 to 2015
$7.0M
Transcriptional silencing by the BCL6 oncoproteinR01CA104348 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MELNICK, ARI M. · 2004 to 2014
$2.6M
Significance and Function of HGAL in LymphomaR01CA109335 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LOSSOS, IZIDORE S · 2005 to 2013
$2.1M
NCI NIH HHS R01 CA104348NCI NIH HHS R01 CA109335NCI NIH HHS R01 CA109335-04A1NHLBI NIH HHS U01 HL099995NHLBI NIH HHS U01 HL099999NHLBI NIH HHS U01HL099999
6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma and can be separated into two subtypes based upon molecular features with similarities to germinal centre B-cells (GCB-like) or activated B-cells (ABC-like). Here we identify gain of 3q27.2 as being significantly associated with adverse outcome in DLBCL and linked with the ABC-like subtype. This lesion includes the BCL6 oncogene, but does not alter BCL6 transcript levels or target-gene repression. Separately, we identify expression of BCL6 in a subset of human haematopoietic stem/progenitor cells (HSPCs). We therefore hypothesize that BCL6 may act by 'hit-and-run' oncogenesis. We model this hit-and-run mechanism by transiently expressing Bcl6 within murine HSPCs, and find that it causes mature B-cell lymphomas that lack Bcl6 expression and target-gene repression, are transcriptionally similar to post-GCB cells, and show epigenetic changes that are conserved from HSPCs to mature B-cells. Together, these results suggest that BCL6 may function in a 'hit-and-run' role in lymphomagenesis.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsB-LymphocytesCyclophosphamideDNA-Binding ProteinsDNA Copy Number VariationsDNA MethylationDoxorubicinEpigenesis, GeneticFemaleHematopoietic Stem CellsHumansLymphoma, Large B-Cell, DiffuseMaleAntibodies, Monoclonal, Murine-DerivedBCL6 protein, humanBcl6 protein, mouseCyclophosphamideDNA-Binding ProteinsDoxorubicinPrednisoneProto-Oncogene Proteins c-bcl-6R-CHOP protocolRituximabVincristine

Identifiers

PMID24887457
PMCPMC4321731
OpenAlexW2039255446

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.